Drug intelligence / Profile preview

D064 + D701

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D064 + D701 is a combination therapy under development by Chong Kun Dang Pharmaceutical. It consists of two small-molecule inhibitors designed to target specific molecular pathways implicated in disease processes. The primary indication for this combination is hypertension, and it has been evaluated in clinical trials for its pharmacokinetic characteristics and safety profile. The latest available data indicate that the drug has completed Phase I clinical trials focused on healthy adults[1][5][8]. Detailed mechanisms of action and molecular targets have not been disclosed publicly.

Other names: D-064/D-701

Beyond the preview

Go deeper on D064 + D701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D064 + D701.

Explore the full profile